There has been a huge fuss about the so-called ‘slimming injection’ for a year now. This is intended to help people lose weight and achieve long-term results. More and more products are coming onto the market, but they are expensive and must be administered once a week. “MariTide,” on the other hand, should only be used once a month.
Weight loss should be easier for obese people. For the first time, American biotech giant Amgen has successfully investigated a weight loss injection in a phase II study (dosage, side effects, further evidence of effectiveness) that only needs to be administered once a month.
“MariTide showed an average weight loss of 20 percent after 52 weeks without reaching a plateau in obese or overweight people,” the report said.
Currently, weekly injections are required
The background: Danish pharmaceutical company Novo Nordisk and its US rival Eli Lilly are currently competing for the multi-billion dollar global market for weekly injected GLP-1 receptor agonists (Semaglutide/Wegovy) and GLP-1/GIP agonists (Tirzepatide/Mounjaro). weight loss medications. This medication should be injected under the skin once a week.
Currently, when comparing the two drugs, Tirzepatide (Eli Lilly) is likely to lead slightly with a 20 percent weight reduction within 72 weeks. Wegovy came to just under 14 percent.
Source: Krone
I am an experienced and passionate journalist with a strong track record in news website reporting. I specialize in technology coverage, breaking stories on the latest developments and trends from around the world. Working for Today Times Live has given me the opportunity to write thought-provoking pieces that have caught the attention of many readers.
